Aduro BioTech Inc (NASDAQ:ADRO) – Equities researchers at Oppenheimer issued their Q1 2019 earnings per share (EPS) estimates for Aduro BioTech in a report released on Monday. Oppenheimer analyst M. Breidenbach forecasts that the biotechnology company will post earnings of ($0.44) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $15.00 target price on the stock. Oppenheimer also issued estimates for Aduro BioTech’s Q2 2019 earnings at ($0.47) EPS and Q3 2019 earnings at ($0.47) EPS.
A number of other analysts have also recently weighed in on ADRO. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Aduro BioTech in a report on Wednesday, September 27th. William Blair restated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. Finally, BidaskClub cut shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Aduro BioTech has an average rating of “Buy” and a consensus target price of $19.14.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the business posted ($0.54) earnings per share. The firm’s quarterly revenue was up .0% on a year-over-year basis.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $9.38, for a total transaction of $375,200.00. Following the completion of the transaction, the insider now directly owns 213,921 shares of the company’s stock, valued at approximately $2,006,578.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Gregory W. Schafer sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $9.34, for a total transaction of $186,800.00. Following the transaction, the chief operating officer now directly owns 155,676 shares of the company’s stock, valued at $1,454,013.84. The disclosure for this sale can be found here. Insiders have sold a total of 264,480 shares of company stock valued at $2,484,317 over the last three months. 6.60% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of ADRO. Legal & General Group Plc increased its holdings in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 1,043 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Aduro BioTech in the 3rd quarter worth $127,000. SG Americas Securities LLC purchased a new stake in Aduro BioTech in the 3rd quarter worth $167,000. Trexquant Investment LP purchased a new stake in Aduro BioTech in the 3rd quarter worth $175,000. Finally, Voya Investment Management LLC increased its holdings in Aduro BioTech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 2,515 shares in the last quarter. 45.19% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Research Analysts Set Expectations for Aduro BioTech Inc’s Q1 2019 Earnings (ADRO)” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/12/research-analysts-set-expectations-for-aduro-biotech-incs-q1-2019-earnings-adro.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.